Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
42(5):1822-1836
quickly equilibrating with the central nervous system
while values in BHK cells were 0
InChiKey: MALFODICFSIXPO-KFKQDBFTSA-N
InChi: InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H
Ruxolitinib sulfate - CAS# 1092939-16-6 alog 2 42(5):1822-1836Ruxolitinib sulfate is the first potent, selective JAK1 2 inhibitor to enter the clinic with IC50s of 3. 3 nM 2. 8 nM, and has > 130 fold selectivity for JAK1 2 versus JAK3. Ruxolitinib potently and selectively inhibits JAK2V617F mediated signaling and proliferation, markedly increases apoptosis in a dose dependent manner, and at 64 nM results in a doubling of cells with depolarized mitochondria in Ba F3 cells. Ruxolitinib demonstrates remarkable